|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kaseb AO, Morris JS, Hassan MM, Siddiqui
AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S and
Abbruzzese JL: Clinical and prognostic implications of plasma
insulin-like growth factor-1 and vascular endothelial growth factor
in patients with hepatocellular carcinoma. J Clin Oncol.
29:3892–3899. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ziol M, Sutton A, Calderaro J, Barget N,
Aout M, Leroy V, Blanc JF, Sturm N, Bioulac-Sage P, Nahon P, et al:
ESM-1 expression in stromal cells is predictive of recurrence after
radiofrequency ablation in early hepatocellular carcinoma. J
Hepatol. 59:1264–1270. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maki RG: Small is beautiful: Insulin-like
growth factors and their role in growth development and cancer. J
Clin Oncol. 28:4895–4995. 2010. View Article : Google Scholar
|
|
5
|
Chan JM, Stampfer MJ, Giovannucci E, Gann
PH, Ma J, Wilkinson P, Hennekens CH and Pollak M: Plasma
insulin-like growth factor-I and prostate cancer risk, A
prospective study. Science. 279:563–566. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hankinson SE, Willett WC, Colditz GA,
Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE and Pollak M:
Circulating concentrations of insulin-like growth factor-I and risk
of breast cancer. Lancet. 351:1393–1396. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ma J, Pollak MN, Giovannucci E, Chan JM,
Tao Y, Hennekens CH and Stampfer MJ: Prospective study of
colorectal cancer risk in men and plasma levels of insulin-like
growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer
Inst. 91:620–625. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Elsammak MY, Amin GM, Khalil GM, Ragab WS
and Abaza MM: Possible contribution of serum activin A and IGF-1 in
the development of hepatocellular carcinoma in Egyptian patients
suffering from combined hepatitis C virus infection and hepatic
schistosomiasis. Clin Biochem. 39:623–629. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
García-Galiano D, Sánchez-Garrido MA,
Espejo I, Montero JL, Costán G, Marchal T, Membrives A,
Gallardo-Valverde JM, Muñoz-Castañeda JR, Arévalo E, et al: IL-6
and IGF-1 are independent prognostic factors of liver steatosis and
non-alcoholic steatohepatitis in morbidly obese patients. Obes
Surg. 17:493–503. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Luo SM, Tan WM, Deng WX, Zhuang SM and Luo
JW: Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and
adjacent non-tumor tissues of hepatocellular carcinoma patients
with cirrhosis. World J Gastroenterol. 11:4272–4276. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Su WW, Lee KT, Yeh YT, Soon MS, Wang CL,
Yu ML and Wang SN: Association of circulating insulin-like growth
factor 1 with hepatocellular carcinoma, One cross-sectional
correlation study. J Clin Lab Anal. 24:195–200. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chun YS, Huang M, Rink L and Von Mehren M:
Expression levels of insulin-like growth factors and receptors in
hepatocellular carcinoma A retrospective study. World J Surg Oncol.
12:2312014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shao YY, Huang CC, Lin SD, Hsu CH and
Cheng AL: Serum insulin-like growth factor-1 levels predict
outcomes of patients with advanced hepatocellular carcinoma
receiving antiangiogenic therapy. Clin Cancer Res. 18:3992–3997.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bruix J and Sherman M: American
association for the study of liver diseases: Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
American Association for the Study of
Liver Diseases: Management of Hepatocellular Carcinoma: An Update.
http://www.aasld.org/publications/practice-guidelines-0Accessed.
September 16–2014
|
|
16
|
Karabulut S, Duranyildiz D, Tas F, Gezer
U, Akyüz F, Serilmez M, Ozgür E, Yasasever CT, Vatansever S and
Aykan NF: Clinical significance of serum circulating insulin-like
growth factor-1 (IGF-1) mRNA in hepatocellular carcinoma. Tumour
Biol. 35:2729–2739. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Malaguarnera G, Giordano M, Paladina I,
Berretta M, Cappellani A and Malaguarnera M: Serum markers of
hepatocellular carcinoma. Dig Dis Sci. 55:2744–2755. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
De Mellow: JS andB axter RC: Growth
hormone-dependent insulin-like growth factor (IGF) binding protein
both inhibits and potentiates IGF-I-stimulated DNA synthesis in
human skin fibroblasts. Biochem Biophys Res Commun. 156:151–156.
1988.
|
|
19
|
Yu H, Spitz MR, Mistry J, Gu J, Hong WK
and Wu X: Plasma levels of insulin-like growth factor-I and lung
cancer risk, A case-control analysis. J Natl Cancer Inst.
91:151–156. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cho E, Kim HC, Lee JH, Yoo JJ, Choi WM,
Cho YY, Lee MJ, Lee YB, Yu SJ, Kim YJ, et al: Serum insulin-like
growth factor-1 predicts disease progression and survival in
patients with hepatocellular carcinoma who undergo transarterial
chemoembolization. PLoS One. 9:e908262014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mazziotti G, Sorvillo F, Morisco F,
Carbone A, Rotondi M, Stornaiuolo G, Precone DF, Cioffi M, Gaeta
GB, Caporaso N and Carella C: Serum insulin-like growth factor I
evaluation as a useful tool for predicting the risk of developing
hepatocellular carcinoma in patients with hepatitis C virus-related
cirrhosis, A prospective study. Cancer. 95:2539–2545. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lorenzo-Zúñiga V, Bartolí R, Masnou H,
Montoliu S, Morillas RM and Planas R: Serum concentrations of
insulin-like growth factor-I (igf-I) as a marker of liver fibrosis
in patients with chronic hepatitis C. Dig Dis Sci. 52:3245–3250.
2007. View Article : Google Scholar : PubMed/NCBI
|
